Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21 EUR | +2.44% | +3.45% | +4.48% |
May. 02 | LNA Santé: 4.9% increase in quarterly sales | CF |
Mar. 28 | LNA Santé: 9% drop in annual RNPG | CF |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 421.4 | 478.1 | 471.3 | 484.3 | 311 | 209.7 | 209.7 | - |
Enterprise Value (EV) 1 | 616.1 | 1,158 | 1,324 | 1,339 | 1,121 | 1,169 | 957.5 | 919.6 |
P/E ratio | 19.6 x | 23 x | 60.5 x | 20.5 x | 11.9 x | 8.78 x | 8.84 x | 8.21 x |
Yield | 0.87% | 0.91% | 0.41% | 0.85% | 1.69% | 2.99% | 2.52% | 2.7% |
Capitalization / Revenue | 0.78 x | 0.91 x | 0.82 x | 0.7 x | 0.43 x | 0.28 x | 0.26 x | 0.24 x |
EV / Revenue | 1.14 x | 2.19 x | 2.31 x | 1.94 x | 1.54 x | 1.59 x | 1.18 x | 1.04 x |
EV / EBITDA | 11.7 x | 10.2 x | 11.4 x | 9.48 x | 7.85 x | 7.85 x | 6.16 x | 5.44 x |
EV / FCF | 16 x | 10.4 x | 9.64 x | 19.2 x | 12.5 x | 13.6 x | 12.5 x | 9.59 x |
FCF Yield | 6.24% | 9.63% | 10.4% | 5.21% | 8.02% | 7.36% | 8.01% | 10.4% |
Price to Book | 2.14 x | 2.53 x | 2.5 x | 2.23 x | - | 0.75 x | 0.67 x | 0.63 x |
Nbr of stocks (in thousands) | 9,677 | 9,650 | 9,569 | 9,629 | 10,508 | 10,227 | 10,227 | - |
Reference price 2 | 43.55 | 49.55 | 49.25 | 50.30 | 29.60 | 20.50 | 20.50 | 20.50 |
Announcement Date | 4/3/19 | 4/1/20 | 3/31/21 | 3/30/22 | 3/29/23 | 3/27/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 538.8 | 527.9 | 573.9 | 689.5 | 728.2 | 736.1 | 811.7 | 887.9 |
EBITDA 1 | 52.88 | 113.9 | 116.5 | 141.2 | 142.8 | 148.8 | 155.5 | 169.1 |
EBIT 1 | 43.97 | 55.12 | 51.38 | 64.81 | 64.31 | 65 | 69.77 | 78.53 |
Operating Margin | 8.16% | 10.44% | 8.95% | 9.4% | 8.83% | 8.83% | 8.6% | 8.84% |
Earnings before Tax (EBT) | 35.7 | 36.45 | 18.64 | 36.25 | - | - | - | - |
Net income 1 | 21.52 | 20.83 | 7.807 | 23.51 | 25.81 | 23.4 | 24.47 | 26.33 |
Net margin | 4% | 3.95% | 1.36% | 3.41% | 3.54% | 3.18% | 3.01% | 2.97% |
EPS 2 | 2.226 | 2.158 | 0.8147 | 2.453 | 2.492 | 2.290 | 2.320 | 2.497 |
Free Cash Flow 1 | 38.47 | 111.5 | 137.4 | 69.68 | 89.86 | 85.98 | 76.73 | 95.87 |
FCF margin | 7.14% | 21.12% | 23.95% | 10.11% | 12.34% | 11.68% | 9.45% | 10.8% |
FCF Conversion (EBITDA) | 72.74% | 97.9% | 117.97% | 49.33% | 62.91% | 57.78% | 49.35% | 56.68% |
FCF Conversion (Net income) | 178.71% | 535.36% | 1,760.45% | 296.38% | 348.1% | 367.42% | 313.62% | 364.05% |
Dividend per Share 2 | 0.3800 | 0.4500 | 0.2000 | 0.4300 | 0.5000 | 0.6000 | 0.5167 | 0.5533 |
Announcement Date | 4/3/19 | 4/1/20 | 3/31/21 | 3/30/22 | 3/29/23 | 3/27/24 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2019 S1 | 2020 S1 | 2021 Q2 | 2021 S1 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 255.5 | 278.3 | 173.6 | 337.3 | 160.1 | 192.1 | 166.4 | 193.5 | 359.9 | 179 | 189.3 | 177 | 186.7 | 363.7 | 176.6 | 198 |
EBITDA | 28.69 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT | 22.9 | 21.6 | - | 30.9 | - | - | - | - | 33.07 | - | - | - | - | 32.2 | - | - |
Operating Margin | 8.96% | 7.76% | - | 9.16% | - | - | - | - | 9.19% | - | - | - | - | 8.85% | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 9/18/19 | - | 9/30/21 | - | 11/4/21 | 3/30/22 | 6/14/22 | 9/14/22 | 9/14/22 | 11/5/22 | 3/29/23 | 5/4/23 | 9/13/23 | 9/13/23 | 11/7/23 | - |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | 195 | 680 | 853 | 854 | 810 | 963 | 748 | 710 |
Net Cash position 1 | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 3.681 x | 5.972 x | 7.324 x | 6.048 x | 5.668 x | 6.472 x | 4.809 x | 4.198 x |
Free Cash Flow 1 | 38.5 | 112 | 137 | 69.7 | 89.9 | 86 | 76.7 | 95.9 |
ROE (net income / shareholders' equity) | 11.4% | 10.8% | 4.3% | 11.5% | 10.2% | 7.95% | 7.47% | 7.6% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share 2 | 20.40 | 19.60 | 19.70 | 22.50 | - | 27.30 | 30.60 | 32.50 |
Cash Flow per Share 2 | 5.240 | 11.30 | 15.30 | 8.330 | - | 14.30 | 11.40 | 12.00 |
Capex 1 | 9.55 | 6.53 | 9.07 | 10.2 | 12 | 11.5 | 15.8 | 17.3 |
Capex / Sales | 1.77% | 1.24% | 1.58% | 1.49% | 1.64% | 1.57% | 1.94% | 1.95% |
Announcement Date | 4/3/19 | 4/1/20 | 3/31/21 | 3/30/22 | 3/29/23 | 3/27/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+2.24% | 226M | |
+16.17% | 82.36B | |
-29.41% | 69.97B | |
+10.99% | 29.41B | |
-11.35% | 16.99B | |
+0.93% | 17.08B | |
-0.68% | 15.21B | |
+1.42% | 11.84B | |
+3.44% | 13.25B | |
+31.43% | 12.08B |
- Stock Market
- Equities
- LNA Stock
- Financials LNA Santé